NCT00923169View on ClinicalTrials.gov

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2006

Primary Completion Date

January 20, 2010

Study Completion Date

January 20, 2010

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Anti-Transforming Growth Factor-beta (GC 1008)

Trial Locations (1)

08901

Cancer Institute of New Jersey, Little Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00923169 - Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | Biotech Hunter | Biotech Hunter